Joseph Ross, MD, MHS
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management)Cards
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
University of Rochester (1996)
Training
Montefiore Medical Center (2004)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
University of Rochester (1996)
Training
Montefiore Medical Center (2004)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
University of Rochester (1996)
Training
Montefiore Medical Center (2004)
About
Copy Link
Titles
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management)
Biography
Joseph S. Ross, MD, MHS, is a Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management), a member of the Center for Outcomes Research and Evaluation (CORE) at the Yale-New Haven Hospital, and an Co-Director of the National Clinician Scholars program (NCSP) at Yale. He completed his undergraduate degrees in biological science: neuroscience and psychology at the University of Rochester and his medical degree at the Albert Einstein College of Medicine, Bronx, NY. After completing his post-graduate training in primary care internal medicine at Montefiore Medical Center in Bronx, NY, Dr. Ross was a fellow in the Robert Wood Johnson Foundation Clinical Scholars program at Yale, earning a Master’s degree in health sciences research. Using health services research methods, Dr. Ross’s research focuses on examining factors which affect the use or delivery of recommended ambulatory care services for older adults and other vulnerable populations, evaluating the impact of state and federal policies on the delivery of appropriate and higher quality care, and addressing issues related to pharmaceutical and medical device regulation, evidence development, postmarket surveillance, and clinical adoption. In addition, he collaborates with a multi-disciplinary team of investigators under contract for the Centers for Medicare and Medicaid Services to develop statistical models that are used to measure and publicly report hospital and ambulatory care clinical outcomes using administrative data. Dr. Ross co-directs the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI), the Yale Open Data Access (YODA) Project, the Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT) at Yale Law School, and leads efforts at Yale-New Haven Health System in collaboration with the National Evaluation System for health Technology. Dr. Ross is currently a Deputy Editor at JAMA, co-founder of medRxiv, Chair of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC), and a member of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) for ICER.
Appointments
General Internal Medicine
ProfessorPrimaryHealth Policy & Management
ProfessorSecondaryInstitution for Social and Policy Studies
ProfessorSecondary
Other Departments & Organizations
- Cancer Prevention and Control
- Center for Outcomes Research & Evaluation (CORE)
- Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT)
- General Internal Medicine
- Health Policy & Management
- Institution for Social and Policy Studies
- Internal Medicine
- National Clinician Scholars Program
- Regulatory Affairs Track
- Yale School of Public Health
- Yale Ventures
Education & Training
- MHS
- Yale School of Medicine (2006)
- Postgraduate Training
- Montefiore Medical Center (2004)
- MD
- Albert Einstein College of Medicine (2001)
- BS
- University of Rochester (1996)
- BA
- University of Rochester (1996)
Research
Copy Link
Overview
Medical Research Interests
Public Health Interests
ORCID
0000-0002-9218-3320
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Harlan Krumholz, MD, SM
Reshma Ramachandran, MD, MPP, MHS
Jeph Herrin, PhD
Jennifer E Miller, PhD
Cary P Gross, MD
Jeptha Curtis, MD
Quality of Health Care
Delivery of Health Care
Health Services Research
Publications
2025
Clinical Characteristics of Adults at Risk of Medicaid Disenrollment Due to HR 1 Work Requirements.
Chetty AK, Ross JS, Chen AS. Clinical Characteristics of Adults at Risk of Medicaid Disenrollment Due to HR 1 Work Requirements. JAMA 2025 PMID: 41032309, DOI: 10.1001/jama.2025.16533.Peer-Reviewed Original ResearchExpanding Prior Authorization in Traditional Medicare—The WISeR Model
Rathi V, Dhruva S, Ross J. Expanding Prior Authorization in Traditional Medicare—The WISeR Model. JAMA 2025, 334 PMID: 40875572, DOI: 10.1001/jama.2025.16326.Peer-Reviewed Original ResearchCitationsAltmetricIndustry payments to US neurologists related to multiple sclerosis drugs and prescribing (2015–2019): a retrospective cohort study
Sayed A, Gupta R, Ramachandran R, Rivero-de-Aguilar A, Ross J. Industry payments to US neurologists related to multiple sclerosis drugs and prescribing (2015–2019): a retrospective cohort study. BMJ Open 2025, 15: e095952. PMID: 40858330, PMCID: PMC12406943, DOI: 10.1136/bmjopen-2024-095952.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPrescription volumePayment recipientsLikelihood of prescribingAssociated with prescribingIndustry paymentsAssociated with greater likelihoodCenters for Medicare & Medicaid Services Open Payments databaseHigh-volume prescribersGeneralised linear mixed modelsCompany's drugMS drugsRetrospective cohort studyMedicare beneficiariesLinear mixed modelsCohort studyMedicaid Services Open Payments databaseGreater likelihoodPrescribingAnnual prescriptionsMultiple sclerosisPrimary outcomeConsultation serviceReceipt of paymentsLarger paymentsMedicare Part D databaseLongitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies
Thanarajasingam G, Bhatnagar V, Noble B, Chen T, Fiero M, Hoffman R, Jeffery M, Mazza G, Mascarenhas J, Mesa R, Murugappan M, Ross J, Sidana S, Warsame R, Kluetz P, Dueck A. Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies. BMC Medical Research Methodology 2025, 25: 189. PMID: 40775758, PMCID: PMC12329971, DOI: 10.1186/s12874-025-02617-y.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsMeSH KeywordsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCross-Sectional StudiesFemaleHematologic NeoplasmsHumansLongitudinal StudiesMaleMiddle AgedMulticenter Studies as TopicPatient Reported Outcome MeasuresQuality of LifeRandomized Controlled Trials as TopicSurveys and QuestionnairesUnited StatesUnited States Food and Drug AdministrationConceptsFood and Drug AdministrationHematologic malignanciesPhysical functionCAR-T cell therapyUS Food and Drug AdministrationPatient-reported physical functionCore patient-reported outcomesPROMIS-29 questionnairePatient-reported outcomesEORTC QLQ-C30CAR-TStacked bar chartsAutologous transplantationMyeloproliferative neoplasmsTolerability endpointsTreatment toleranceMultiple myelomaBackgroundThe US Food and Drug AdministrationCell therapyClinical trialsMalignancyCancer clinical trialsPatient stakeholdersPROMIS-29Fact QuestionnaireStrength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
Zhang Y, Chen D, Fu M, Shi L, Naci H, Wagner A, Ross J, Guan X. Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. The Lancet Oncology 2025, 26: 1252-1260. PMID: 40782821, DOI: 10.1016/s1470-2045(25)00329-8.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRandomised controlled trialsSingle-arm trialRisk of biasCancer drug indicationsRatio of hazard ratiosHigh risk of biasHigh riskStrength of evidenceRetrospective analysisNational Natural Science FoundationEffect sizeLow riskCancer drugsCancer drug approvalsLow risk of biasDrug efficacy dataRisk-of-bias assessmentChina National Knowledge Infrastructure databasesNational Knowledge Infrastructure databasesNovel cancer drugsDrug indicationsPivotal studiesProphylactic vaccinesNational Natural Science Foundation of ChinaClinical evidenceFDA Authorization of Therapeutic Devices Under the Breakthrough Devices Program
Kadakia K, Dhruva S, Ross J, Burke J, Johnston J, Ramachandran R, Krumholz H, Rathi V. FDA Authorization of Therapeutic Devices Under the Breakthrough Devices Program. JAMA Internal Medicine 2025, 185: 996-1004. PMID: 40587167, PMCID: PMC12210143, DOI: 10.1001/jamainternmed.2025.2235.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsFood and Drug AdministrationFDA review timesFood and Drug Administration authorityFood and Drug Administration dataShort follow-up durationUS Food and Drug AdministrationFollow-up durationDevice programmingEffectiveness end pointCross-sectional studyHigh-risk devicesSurrogate measureTarget timeframePostmarketing studiesMain OutcomesEnd pointsPatient accessDrug AdministrationHigh riskClass IStudy characteristicsTherapeutic devicesClinical testingSurrogate measures of effectivenessMeasures of effectivenessAnticoagulation therapy for patients with atrial fibrillation at primary care facilities in Beijing, China, 2017–2022
Fu M, Ling K, Gong Z, Dong S, Li H, Wang F, Xu Y, Shi L, Ross J, Guan X. Anticoagulation therapy for patients with atrial fibrillation at primary care facilities in Beijing, China, 2017–2022. Thrombosis Research 2025, 253: 109417. PMID: 40752480, DOI: 10.1016/j.thromres.2025.109417.Peer-Reviewed Original ResearchDemographic Data Supporting FDA Authorization of AI Devices for Alzheimer Disease and Related Dementias
Chen K, Ross J, Cohen A, Karlawish J, Oh E, Gupta R. Demographic Data Supporting FDA Authorization of AI Devices for Alzheimer Disease and Related Dementias. JAMA 2025, 334 PMID: 40736371, PMCID: PMC12311817, DOI: 10.1001/jama.2025.12779.Peer-Reviewed Original ResearchAltmetricExclusion of Older Adults from Obesity Treatment Pivotal Trials of GLP-1RAs and GIP/GLP-1RAs
Chen A, Liang Y, Lipska K, Ross J, Ramachandran R. Exclusion of Older Adults from Obesity Treatment Pivotal Trials of GLP-1RAs and GIP/GLP-1RAs. Journal Of General Internal Medicine 2025, 1-3. PMID: 40728804, DOI: 10.1007/s11606-025-09769-z.Peer-Reviewed Original ResearchAltmetricRelationship between industry payments to physicians and prescription patterns for PCSK9is, ARNis and DOACs: A report from the NCDR PINNACLE registry
Annapureddy A, Murugiah K, Zheng L, Minges K, Grandhi G, Ross J, Ahmad T, Rodwin B, Dhruva S, Girotra S, Dayoub E, Curtis J, Desai N. Relationship between industry payments to physicians and prescription patterns for PCSK9is, ARNis and DOACs: A report from the NCDR PINNACLE registry. American Heart Journal 2025, 291: 26-36. PMID: 40714034, DOI: 10.1016/j.ahj.2025.07.015.Peer-Reviewed Original ResearchAltmetricConceptsAngiotensin receptor-neprilysin inhibitorDirect oral anticoagulantsProprotein convertase subtilisin/kexin type 9Nonvalvular atrial fibrillationProprotein convertase subtilisin/kexin type 9 inhibitorsAtherosclerotic cardiovascular diseasePINNACLE RegistryDirect oral anticoagulant prescribingNonvalvular atrial fibrillation patientsReduced ejection fractionProportion of patientsAtherosclerotic cardiovascular disease patientsNo significant associationAssociated with prescribingPCSK inhibitorsHFrEF patientsOral anticoagulantsIndustry paymentsEjection fractionHFrEF cohortPCSK9 inhibitorsPatient cohortAtrial fibrillationPrescription patternsHeart failure
Academic Achievements & Community Involvement
Copy Link
Activities
activity JAMA
06/01/2023 - PresentJournal ServiceDeputy Editoractivity BMJ
2020 - 2023Journal ServiceAssociate Editoractivity JAMA Internal Medicine
04/01/2013 - 12/31/2019Journal ServiceAssociate Editoractivity Journal of General Internal Medicine
2011 - 2013Journal ServiceDeputy Editor
News
Copy Link
News
- November 03, 2025Source: JAMA
Dean Megan Ranney contributes to new report aimed at reducing firearm violence
- October 21, 2025Source: Yale News
IV Hydration Spas Lack Adequate Oversight, Study Finds
- September 18, 2025Source: U.S. News & World Report
Pharma Payments Might Influence MS Drug Prescriptions, Researchers Argue
- September 16, 2025
Fellow Focus in Four: Joshua Skydel, MD, Rheumatology, Allergy, and Immunology
Get In Touch
Copy Link
Contacts
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Locations
E.S. Harkness Memorial Hall, Building A
Academic Office
367 Cedar Street, Ste 405B
New Haven, CT 06510